Impact of Therapeutic Educational Programme on the Alzheimer's Disease Affected Patient's Quality of Life (THERAD)
Primary Purpose
Alzheimer Disease
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Therapeutic Educational Program
Sponsored by
About this trial
This is an interventional supportive care trial for Alzheimer Disease focused on measuring Therapeutic educational programme for Alzheimer's disease patients and their caregiver, Alzheimer's disease, mild to moderately severe stages, Community dwelling patients with family caregiver, quality of life
Eligibility Criteria
Inclusion Criteria:
- patient suffering from mild to moderately severe Alzheimer's disease patients (MMSE 11 to 26)
- in community dwelling
- with an informal caregiver (person living with the patient or providing care 3 times a week or 8 hours per week)
- is informed and has given his/her consent
- whom caregiver is informed and has given his/her consent
Exclusion Criteria:
- patient with other type of dementia
- living in nursing home or long term care
- with no caregiver
- not informed or has not given his/her consent
- whom caregiver is not informed or has not given his/her consent
Sites / Locations
- CHU de Toulouse, Hôtel-Dieu, 2 rue Viguerie
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Group A : intervention
Group B : Control
Arm Description
85 dyads "patient/caregiver" in witch the patient suffers from mild to moderately severe Alzheimer's disease patients (MMSE 11 to 26), and lives at home with a caregiver
There si no associated intervention
Outcomes
Primary Outcome Measures
Alzheimer's Disease patient's quality of life
Alzheimer's Disease patient's quality of life assessed by Logsdon's Quality of life in Alzheimer's Disease scale (QoL-AD) reported by the caregiver
Secondary Outcome Measures
Caregiver quality of life
Caregiver's burden assessed by the Zarit Burden Inventory
Frequency and severity of behavioural and psychological symptoms assessed by the Neuro Psychiatric inventory
Independence in personal and instrumental daily life activities assessed by Katz's Activities of Daily Living and Lawton's Instrumental Activities of Daily Living scales
Caregiver's quality of life assessed by the Nottingham Health Profile at 6 months
Patient quality of life at 6 and 12 months on the Logsdon's Quality of Life in Alzheimer's Disease scale reported by the caregiver
Patient quality of life at 2,6 and 12 months on the Logsdon's Quality of Life in Alzheimer's Disease scale reported by the patient himself
Full Information
NCT ID
NCT01796314
First Posted
February 19, 2013
Last Updated
October 26, 2021
Sponsor
University Hospital, Toulouse
1. Study Identification
Unique Protocol Identification Number
NCT01796314
Brief Title
Impact of Therapeutic Educational Programme on the Alzheimer's Disease Affected Patient's Quality of Life
Acronym
THERAD
Official Title
Impact of a Therapeutic Educational Programme for Alzheimer's Disease Patients and Their Caregiver in Community Dwelling, on the AD Patient's Quality of Life
Study Type
Interventional
2. Study Status
Record Verification Date
October 2021
Overall Recruitment Status
Completed
Study Start Date
January 2013 (undefined)
Primary Completion Date
February 2017 (Actual)
Study Completion Date
February 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Toulouse
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Therapeutic education expands in Alzheimer's Disease management in France. Several studies revealed a positive impact on caregiver's burden and/or quality of life. The purpose of this study, is to determine whether a therapeutic educational programme for both AD patients and primary caregivers, in community dwelling, improves patient's quality of life.
Detailed Description
This study is designed to determine whether a therapeutic educational programme for both AD patients, in community dwelling, and their primary caregivers improves patient's quality of life, after two months.
Design : This study is a monocentric randomised controlled intervention trial
Population : One hundred and seventy dyads 'patient-caregiver' in which the patient suffers from mild to moderately severe Alzheimer's disease patients (MMSE 11 to 26), lives in community dwelling and has a primary caregiver will be included during eighteen months. The primary caregiver is define as a person living with the patient or providing care at least 3 times a week or 8 hours per week; he/she isn't a professional. Eighty five dyad will be include in the intervention group (group A) and eighty five in the control group (group B).
Outcome : Our primary endpoint is the AD patient's quality of life assessed by Logsdon's Quality of life in Alzheimer's Disease scale (Qol-AD) reported by the caregiver at two months.
Our secondary endpoints are caregiver's burden assessed by the Zarit Burden Inventory, frequency and severity of behavioural and psychological symptoms assessed by the Neuro Psychiatric Inventory, independence in personal and instrumental daily life activities assessed by Katz's Activities of Daily Living and Lawton's Instrumental Activities of Daily Living scales, and caregiver's quality of life assessed by the Nottingham Health Profile at 6 months. The patient quality of life will also be recorded at 12 months on the logsdon's Quality of Life in Alzheimer's Disease scale reported, and at every visit (MO, M2, M6, et M12) on the same scale dut (QoL-AD) reported by the patient himself.
Intervention :
The intervention is a therapeutic educational programme. It includes two consultations for the dyad AD patient/caregiver and four group sessions, one a week, for caregivers only. The intervention length is 2 months.
The intervention group (n=85) will benefit from an educational programme that includes two consultations for the dyad AD patient/caregiver and four group sessions for caregivers only. The two consultations will be held at baseline (MO) and two months later (M2); the first one (MO)will include : the 'educational diagnosis', the comprehensive assessment of the patient and assessment of the judgement criteria. Between MO and M2 the primary caregivers will participate to four collective sessions one per week about, of 3 hours length : 1- Knowledge of the disease; 2- Pharmacological and non pharmacological treatments. Behavioural and psychological symptoms of dementia 3- Crisis situations. Prevention of caregiver's exhaustion 4- Assistive devices and care pathways. At M2, the dyad will benefit from : assessment of response to the educational objectives and of the judgement criteria.
The control group (n=85) will benefit from routine care.
The intervention will be implemented over an eighteen month period.
Monitoring will consist of a two consultations to 6 and 12 months including assessment of primary and secondary judgment criteria.
Data collection :
Data will be collected in Access data basis and SAS software will be used to perform statistic analysis. Intention to treat analysis using linear mixed model will be performed, adjusting for patient (disease severity), caregiver characteristics (burden) and occurence of life event that may interfere with the patient's quality of life.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alzheimer Disease
Keywords
Therapeutic educational programme for Alzheimer's disease patients and their caregiver, Alzheimer's disease, mild to moderately severe stages, Community dwelling patients with family caregiver, quality of life
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
170 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Group A : intervention
Arm Type
Experimental
Arm Description
85 dyads "patient/caregiver" in witch the patient suffers from mild to moderately severe Alzheimer's disease patients (MMSE 11 to 26), and lives at home with a caregiver
Arm Title
Group B : Control
Arm Type
No Intervention
Arm Description
There si no associated intervention
Intervention Type
Behavioral
Intervention Name(s)
Therapeutic Educational Program
Other Intervention Name(s)
Therapeutic education programme
Intervention Description
The intervention is a therapeutic educational programme as recommended in the care of Alzheimer's disease. It includes two consultations for the dyad AD patient/caregiver and four group sessions, one a week, for caregivers only. The intervention length is 2 months.
These collective sessions focus on :
Knowledge of the disease
Pharmacological and non pharmacological treatments. Behavioural and psychological symptoms of dementia
Crisis situations. Prevention of caregiver's exhaustion
Assistive devices and care pathways.
Monitoring will consist of a two consultations to 6 and 12 months including assessment of secondary outcome measures.
Primary Outcome Measure Information:
Title
Alzheimer's Disease patient's quality of life
Description
Alzheimer's Disease patient's quality of life assessed by Logsdon's Quality of life in Alzheimer's Disease scale (QoL-AD) reported by the caregiver
Time Frame
2 months
Secondary Outcome Measure Information:
Title
Caregiver quality of life
Description
Caregiver's burden assessed by the Zarit Burden Inventory
Frequency and severity of behavioural and psychological symptoms assessed by the Neuro Psychiatric inventory
Independence in personal and instrumental daily life activities assessed by Katz's Activities of Daily Living and Lawton's Instrumental Activities of Daily Living scales
Caregiver's quality of life assessed by the Nottingham Health Profile at 6 months
Patient quality of life at 6 and 12 months on the Logsdon's Quality of Life in Alzheimer's Disease scale reported by the caregiver
Patient quality of life at 2,6 and 12 months on the Logsdon's Quality of Life in Alzheimer's Disease scale reported by the patient himself
Time Frame
2, 6 and 12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
patient suffering from mild to moderately severe Alzheimer's disease patients (MMSE 11 to 26)
in community dwelling
with an informal caregiver (person living with the patient or providing care 3 times a week or 8 hours per week)
is informed and has given his/her consent
whom caregiver is informed and has given his/her consent
Exclusion Criteria:
patient with other type of dementia
living in nursing home or long term care
with no caregiver
not informed or has not given his/her consent
whom caregiver is not informed or has not given his/her consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hélène VILLARS, MD
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU de Toulouse, Hôtel-Dieu, 2 rue Viguerie
City
Toulouse
ZIP/Postal Code
31052
Country
France
12. IPD Sharing Statement
Citations:
PubMed Identifier
34511121
Citation
Villars H, Cantet C, de Peretti E, Perrin A, Soto-Martin M, Gardette V. Impact of an educational programme on Alzheimer's disease patients' quality of life: results of the randomized controlled trial THERAD. Alzheimers Res Ther. 2021 Sep 12;13(1):152. doi: 10.1186/s13195-021-00896-3.
Results Reference
result
PubMed Identifier
25478028
Citation
Villars H, Gardette V, Perrin A, Hein C, Elmalem S, de Peretti E, Zueras A, Vellas B, Nourhashemi F. Study protocol: Randomised controlled trial to evaluate the impact of an educational programme on Alzheimer's disease patients' quality of life. Alzheimers Res Ther. 2014 Oct 27;6(5-8):66. doi: 10.1186/s13195-014-0066-1. eCollection 2014.
Results Reference
derived
Learn more about this trial
Impact of Therapeutic Educational Programme on the Alzheimer's Disease Affected Patient's Quality of Life
We'll reach out to this number within 24 hrs